- Home
- TILE vs ARVN Comparison
TILE vs ARVN Comparison
Compare TILE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- ARVN
- Stock Information
- Founded
- TILE 1973
- ARVN 2015
- Country
- TILE United States
- ARVN United States
- Employees
- TILE N/A
- ARVN N/A
- Industry
- TILE Home Furnishings
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- ARVN Health Care
- Exchange
- TILE Nasdaq
- ARVN Nasdaq
- Market Cap
- TILE 1.3B
- ARVN 1.4B
- IPO Year
- TILE N/A
- ARVN 2018
- Fundamental
- Price
- TILE $21.48
- ARVN $17.77
- Analyst Decision
- TILE Buy
- ARVN Strong Buy
- Analyst Count
- TILE 2
- ARVN 12
- Target Price
- TILE $22.00
- ARVN $58.82
- AVG Volume (30 Days)
- TILE 416.8K
- ARVN 1.0M
- Earning Date
- TILE 02-25-2025
- ARVN 02-11-2025
- Dividend Yield
- TILE 0.19%
- ARVN N/A
- EPS Growth
- TILE 11277.07
- ARVN N/A
- EPS
- TILE 1.44
- ARVN N/A
- Revenue
- TILE $1,305,766,000.00
- ARVN $263,399,999.00
- Revenue This Year
- TILE $6.86
- ARVN N/A
- Revenue Next Year
- TILE $3.56
- ARVN $1.63
- P/E Ratio
- TILE $14.86
- ARVN N/A
- Revenue Growth
- TILE 2.66
- ARVN 235.54
- 52 Week Low
- TILE $13.07
- ARVN $16.61
- 52 Week High
- TILE $27.34
- ARVN $51.51
- Technical
- Relative Strength Index (RSI)
- TILE 30.83
- ARVN 44.33
- Support Level
- TILE $22.05
- ARVN $17.19
- Resistance Level
- TILE $23.44
- ARVN $20.38
- Average True Range (ATR)
- TILE 0.61
- ARVN 1.38
- MACD
- TILE -0.14
- ARVN 0.08
- Stochastic Oscillator
- TILE 7.58
- ARVN 30.77
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments - AMS and EAAA.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.